Startup Deep Dive : PharmEasy — worth $5.6 billion in 2021, valued near $710 million by 2024

In October 2021, investors put a $5.6 billion price tag on API Holdings, the parent of online pharmacy PharmEasy — India’s most valuable e-pharmacy, fresh off buying a listed diagnostics chain with borrowed money. By April 2024, a rights issue priced the same company at $710 million, a cut of roughly 90%, as reported by Business Standard and TechCrunch.

The medicine business underneath that number never stopped running. Revenue stayed in the ₹5,600–6,600 crore band every year from FY22 to FY25. What collapsed was the story investors had been told about where that revenue was going — and the debt taken on to buy a company that was supposed to make the story bigger.

Quick facts

What they do

PharmEasy sells medicines. That sentence sounds too simple for a company that was once worth more than most listed Indian pharma majors, but it is the honest starting point. The consumer-facing app lets people in Indian cities and towns order prescription drugs, over-the-counter products, and diagnostic tests for home collection, and book teleconsultations, with delivery typically promised within a day or two. Layered on top of that retail business is a diagnostics arm built around Thyrocare, the listed lab-testing chain PharmEasy took control of in 2021, and a business-to-business distribution operation, Aknamed, which supplies medicines and consumables directly to hospitals, clinics and retail chemists rather than to individual patients. Consumers are the visible business; the chemist- and hospital-facing distribution trade is the less-discussed one that, in some years, has carried a meaningful share of revenue.

The origin

Dharmil Sheth and Dhaval Shah started PharmEasy in Mumbai in 2015. Sheth, an electronics engineer with an MBA from IIM Ghaziabad, was already running a separate events business, 91Streets, when he and Shah decided to pivot into pharmacy aggregation. Shah brought a different kind of credibility: an MBBS degree, an MBA from XLRI Jamshedpur, and a stint as a consultant at McKinsey & Company, which he left to build the company full-time. Three more school friends from Ghatkopar — Siddharth Shah, Hardik Dedhia and Harsh Parekh — joined as co-founders soon after, giving the company five people who had known each other since childhood at the top of the cap table.

The founding insight was unglamorous and specific: India’s neighbourhood chemists routinely ran out of stock, prices varied from shop to shop with no way to compare them, and for a chronically ill or elderly patient, a monthly trip to refill a prescription was a real physical burden. PharmEasy’s original model did not try to replace the chemist; it aggregated orders across a network of local pharmacies and delivered to the customer’s door, turning fragmented retail inventory into something that behaved like a single online store.

The struggle years

The first real test of that model was competitive, not existential: by 2019 the online pharmacy race in India had at least three well-funded players — PharmEasy, Medlife and Reliance-backed Netmeds — burning cash to buy market share with near-identical inventory. PharmEasy’s answer was consolidation. It merged with rival Medlife in a deal cleared by the Competition Commission of India in September 2020 and completed in January 2021, valuing Medlife shareholders’ combined stake at $250 million and folding them into an entity then worth around $1.2 billion, with Medlife holders getting 19.59% of the merged company, as reported by Inc42 and Business Standard. Medlife’s app and brand were discontinued and its users migrated onto PharmEasy.

The second setback was self-inflicted and far more expensive. In June 2021, PharmEasy agreed to buy a 66.1% stake in Thyrocare Technologies, a profitable, listed diagnostics chain, for ₹4,546 crore (about $613.5 million), reported by TechCrunch and ETV Bharat. The deal was funded almost entirely with debt: a ₹2,200 crore loan from Kotak Mahindra Bank was taken out to close the acquisition, and in May 2022 that loan was refinanced with a larger, costlier ₹2,700 crore facility from Goldman Sachs, which TechCrunch reported at around $300 million. The company had bought growth and diversification, but it had also bought a large, fixed debt-service obligation onto a business that did not yet generate cash to comfortably cover it.

The third setback came from the market itself. Having filed draft papers for an initial public offering in November 2021, seeking to raise ₹6,250 crore, API Holdings withdrew its DRHP in August 2022, citing “market conditions and strategic considerations”, as reported by Entrackr and Bloomberg. The IPO window that PharmEasy had built its balance sheet around — pricey acquisition debt to be repaid or refinanced once public markets validated the valuation — simply closed. From there, the company moved to sharp cost-cutting: hundreds of jobs were cut in a December 2022 restructuring, and by May 2023 layoffs had touched roughly 1,200 people, about 40% of the workforce, according to Inc42’s reporting at the time. Marketing spend, the fuel of the earlier growth-share war, was cut by more than half, from ₹494 crore in FY22 to ₹235 crore in FY23.

By June 2023, PharmEasy had breached a covenant on its Goldman Sachs loan after failing to raise a required $120 million in fresh equity, YourStory and Inc42 reported. The company kept making its debt payments on time, but the covenant breach was a formal signal that the financing structure built around the Thyrocare deal had run out of room.

The turning point

The turning point was a down round that most founders would call a defeat: the rights issue that closed in April 2024. On one side of that transaction sat the October 2021 peak, when secondary and primary share sales together valued API Holdings at $5.6 billion — a figure reported by both TechCrunch and Business Standard. On the other side sat an April 2024 regulatory filing showing the company had raised about $216 million through a rights issue priced at a roughly 90% discount to that peak, implying a valuation near $710 million, as reported by Business Standard, Entrackr and Outlook Business. Existing shareholders, led by Ranjan Pai’s Manipal Education and Medical Group with a contribution of about ₹800 crore, alongside Prosus, Temasek and 360 One, funded the round rather than new outside money — a sign that no fresh investor was willing to underwrite the old story at anything close to the old price. The proceeds went toward clearing the Goldman Sachs debt that the Thyrocare deal had created. It was, functionally, the moment control of the company passed from its founders and growth-stage backers to the investor who was willing to write the largest cheque to keep it solvent.

The money behind it

PharmEasy has raised roughly $1.96 billion in total across some 14 rounds over a decade, per Inc42’s funding tracker, though the company has not published an audited lifetime total and this figure should be read as reported rather than confirmed. Three backers changed its trajectory in different ways. Prosus Ventures and TPG Growth led the $350 million round in April 2021 that first pushed PharmEasy into unicorn territory and set up the aggressive acquisition spree that followed. Temasek, an existing investor, stayed in through both the boom and the down round, participating again in the 2024 rights issue. Most consequentially, Ranjan Pai’s Manipal Education and Medical Group entered as the anchor investor in the 2023–24 rescue financing, put in the single largest tranche of the rights issue, and effectively took control of the company’s direction — culminating in the August 2025 move that installed Thyrocare’s own chief executive, Rahul Guha, as MD and CEO of API Holdings in place of co-founder Siddharth Shah, who stepped back into a Vice Chairman role, as reported by Entrepreneur India. Four of PharmEasy’s five co-founders — Dharmil Sheth, Dhaval Shah, Hardik Dedhia and Harsh Parekh — had already stepped down from executive roles in January 2025 to start a new consumer venture, according to Inc42, remaining only as shareholders and board observers.

How it makes money

Underneath the funding headlines, PharmEasy runs two different kinds of business with two different economics. The larger one, which the company calls “sale of products”, is retailing medicines, OTC health products and private-label items to consumers and to chemists and hospitals through Aknamed; this is a thin-margin, inventory-heavy, logistics-dependent trade, no different in its underlying economics from running a chain of pharmacies, just online. The smaller one, “sale of services”, is diagnostics and teleconsultation, built mostly around Thyrocare’s lab-testing network, which carries structurally better margins because a blood test costs far less to fulfil than a box of medicine costs to source, store and deliver.

What people get wrong about PharmEasy is assuming that because it is an app, it should carry software-like margins. It does not, and its own FY25 disclosures make the point plainly: Entrackr reported the company spent about ₹1.23 for every ₹1 of revenue it earned that year, and posted an EBITDA loss of roughly ₹553.5 crore even after two years of aggressive cost-cutting. The real margin in this business sits in diagnostics and in controlling customer-acquisition cost, not in the medicine-delivery transaction itself — which is precisely why the marketing-budget cuts of FY23, and the broader shift from growth-at-any-cost to cost discipline, mattered more to the company’s survival than any product feature.

The numbers

Two things stand out. First, revenue has essentially gone nowhere in four years — it fell in FY24 as the company pulled back on marketing and low-quality growth, then recovered only slightly in FY25. Second, the FY23 net loss of ₹5,212 crore, reported by Entrackr, is the accounting scar of the Thyrocare-debt period: a single year in which losses briefly outran revenue, before two consecutive years of disciplined cost-cutting brought the loss down by more than 70% from that peak.

Where the money comes from

The split between PharmEasy’s two business lines has barely moved despite years of talk about diversification. In FY23, sale of pharmaceutical and cosmetic products brought in ₹5,925.3 crore against ₹701.2 crore from diagnostics and other services — a roughly 89:11 split. By FY25, Entrackr reported operating revenue of ₹5,097.5 crore from products against the remainder from diagnostics, teleconsultation and other services, an 87:13 split. The surprise is how little that ratio has shifted. Thyrocare was bought for over $600 million specifically to change PharmEasy’s revenue mix toward higher-margin services; three to four years later, the core, thinner-margin medicine-retailing business still generates roughly seven out of every eight rupees the company takes in. Geographically, the business remains India-only, with no disclosed material international revenue.

The risks

Three risks sit under the recovery narrative. The first is structural dilution risk: the 2023–24 down round was priced so far below earlier funding rounds that it risked triggering anti-dilution ratchet clauses in some investors’ original term sheets, which, as Medical Buyer reported, could force further share issuance to protect those investors’ original per-share cost — diluting everyone else again even after the recapitalisation was meant to draw a line under the crisis. The second is competitive share loss that happened precisely during the cost-cutting years: Business Standard reported that Tata 1mg overtook PharmEasy in e-pharmacy gross merchandise value, holding 31% share by September 2023 against PharmEasy’s 15%, down from roughly 33% a year earlier, as Reliance-backed Netmeds, Apollo 24/7 and, more recently, Amazon Pharmacy also compete for the same customers PharmEasy once dominated. The third is that profitability is still not there at the operating level: Entrackr’s FY25 numbers show an EBITDA loss of about ₹553.5 crore, meaning the improvement in the bottom line has come mostly from lower finance costs after the debt clean-up, not from the core retail business turning structurally profitable.

The takeaway

A funding-round valuation is an opinion, not cash in the bank, and it is only tested when a company actually needs new money from people who were not already emotionally or financially invested in the old story. PharmEasy’s five years show what happens when a fast-growing company borrows heavily against a valuation that has never been priced by an outside buyer: the debt is real and due on schedule regardless of what happens to the paper number attached to the equity. What stabilised the company in the end was not a return to growth but a patient, strategic anchor investor — a hospital-and-education conglomerate with a reason to want the business to survive, not just a fund with a reason to mark it up — willing to fund a recapitalisation at a price everyone could agree was honest.

Frequently asked questions

What is PharmEasy?

PharmEasy is an Indian online pharmacy and healthcare platform, owned by API Holdings Ltd, that sells prescription and over-the-counter medicines, books diagnostic tests through its Thyrocare subsidiary, offers teleconsultations, and distributes pharmaceuticals to chemists and hospitals through its Aknamed arm.

Why did PharmEasy’s valuation fall so much?

API Holdings borrowed heavily, largely through a Goldman Sachs-refinanced loan, to fund its 2021 acquisition of a majority stake in Thyrocare. When its planned IPO was withdrawn in August 2022 and it could not refinance that debt on favourable terms, it was forced into a 2024 rights issue priced at roughly a 90% discount to its 2021 peak valuation, as reported by Business Standard and TechCrunch.

Who owns PharmEasy now?

API Holdings remains privately held. Ranjan Pai’s Manipal Education and Medical Group became the anchor investor in the 2023–24 rescue financing, alongside existing backers Prosus, Temasek and 360 One. Rahul Guha, previously CEO of Thyrocare, became MD and CEO of API Holdings from 27 August 2025.

Is PharmEasy planning an IPO?

API Holdings withdrew its draft IPO papers in August 2022 and has not filed fresh ones as of this writing. Its subsidiary Thyrocare has been separately listed on the NSE and BSE since 2016.

How does PharmEasy make money?

Most of its revenue, around 87% in FY25 per Entrackr, comes from selling medicines and health products to consumers and institutions, a low-margin, logistics-heavy business. The remainder comes from higher-margin diagnostics and teleconsultation services, mainly through Thyrocare.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• TechCrunch, September 2024 — “PharmEasy still 92% below its peak $5.6 billion valuation, investor estimates”
• TechCrunch, July 2023 — “PharmEasy, once valued at over $5 billion, seeks new funding at a 90% valuation cut”
• TechCrunch, June 2021 — “PharmEasy to acquire majority stake in Thyrocare for $613M”
• Business Standard, May 2023 — “Janus Henderson marks down PharmEasy’s valuation by half to $2.8 bn”
• Business Standard, April 2024 — “Online pharmacy PharmEasy raises $216 million at a 90% cut in valuation”
• Business Standard, November 2023 — “Tata 1mg overtakes PharmEasy as leaders in India’s e-pharmacy market”
• Business Standard, 2021 — “PharmEasy buys Medlife, becomes India’s largest e-pharma firm with 2 mn customers”
• Entrackr, December 2022 — “PharmEasy’s scale crosses Rs 5,700 Cr in FY22, losses mount 4X”
• Entrackr, November 2024 — “PharmEasy cuts losses by 51% to Rs 2,533 Cr in FY24, revenue dips 15%”
• Entrackr, September 2025 — “PharmEasy reports Rs 5,872 Cr revenue in FY25; burn remains flat”
• Entrackr, September 2024 — “PharmEasy valuation slashed to $458 Mn by Janus Henderson”
• Outlook Business — “PharmEasy Raises $216 Million At 90% Valuation Cut: Report”
• Inc42, January 2025 — “PharmEasy Cofounders Step Down To Start New Venture”
• Inc42, 2023 — “PharmEasy’s Sales Cross INR 6,000 Cr Mark In FY23, Posts INR 5,211 Cr Loss”
• Inc42 — PharmEasy company funding tracker (total funding and investor list)
• Entrepreneur India, August 2025 — “Thyrocare CEO Rahul Guha to Lead PharmEasy as Siddharth Shah Steps Down”
• Medical Buyer — “PharmEasy’s downround to trigger anti-dilution clauses in investors’ agreements”
• Entrackr, August 2022 — “PharmEasy’s parent API Holdings postpones IPO citing market conditions”
• ETV Bharat, June 2021 — “Pharmeasy acquires Thyrocare in Rs 4,546 crore deal”
• YourStory, June 2023 — “PharmEasy breaches Goldman Sachs loan covenant after failing to raise equity”
• Wikipedia — “PharmEasy” and “Thyrocare” (founder background and listing history, cross-checked against primary reporting above)

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.